Metabolic Rescue of Obese Adipose-Derived Stem Cells by Lin28/Let7 Pathway

  1. Beatriz G. Gálvez1
  1. 1Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  2. 2Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain.
  3. 3University Hospital of Tarragona Joan XXIII, Pere Virgili Institute and Rovira i Virgili University,Tarragona, Spain.
  4. 4El Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.
  1. Corresponding author: Beatriz G. Gálvez, bgonzalez{at}cnic.es.
  • Deceased.

Abstract

Adipose-derived stem cells (ASCs) are promising candidates for autologous cell-based regeneration therapies by virtue of their multilineage differentiation potential and immunogenicity; however, relatively little is known about their role in adipose tissue physiology and dysfunction. Here we evaluated whether ASCs isolated from nonobese and obese tissue differed in their metabolic characteristics and differentiation potential. During differentiation to mature adipocytes, mouse and human ASCs derived from nonobese tissues both increased their insulin sensitivity and inhibition of lipolysis, whereas obese-derived ASCs were insulin-resistant, showing impaired insulin-stimulated glucose uptake and resistance to the antilipolytic effect of insulin. Furthermore, obese-derived ASCs showed enhanced release of proinflammatory cytokines and impaired production of adiponectin. Interestingly, the delivery of cytosol from control ASCs into obese-derived ASCs using a lipid-based, protein-capture methodology restored insulin sensitivity on glucose and lipid metabolism and reversed the proinflammatory cytokine profile, in part due to the restoration of Lin28 protein levels. In conclusion, glucose and lipid metabolism as well as maturation of ASCs is truncated in an obese environment. The reversal of the altered pathways in obese cells by delivery of normal subcellular fractions offers a potential new tool for cell therapy.

Footnotes

  • Received September 5, 2012.
  • Accepted February 10, 2013.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

| Table of Contents

This Article

  1. Diabetes vol. 62 no. 7 2368-2379
  1. Supplementary Data
  2. All Versions of this Article:
    1. db12-1220v1
    2. 62/7/2368 most recent